Octave Bioscience, a commercial stage precision care company that is pioneering a new standard for managing multiple sclerosis (MS) and other neurodegenerative diseases, has announced the close of its $35.6 million Series C equity financing and that it has entered into a $15.5 million non-dilutive term loan agreement with Silicon Valley Bank (SVB) a Division of First Citizens Bank.

The equity round included participation from new strategic investors as well as participation by existing investors including Byers Capital, Blue Venture Fund, Northpond Ventures, S32, Casdin Capital, Merck Global Health Innovation Fund, Novartis, Valhalla Foundation, Intermountain Ventures and Hikma Ventures.

Octave Bioscience is a commercial stage precision care company pioneering biomarker-driven solutions for neurodegenerative diseases, with initial focus on Multiple Sclerosis, and Parkinson's Disease in partnership with Michael J. Fox Foundation. Octave's comprehensive testing solutions provide objective, actionable insights to improve disease monitoring, treatment decisions, and patient outcomes.